RGC Company Profile and Key Details

RGC has shown sold momentum, gaining 97.24% over the past week and 106.58% over the past quarter, though year-to-date performance is up 97.24%. Short-term trend indicators are bearishly aligned (SMA20 81.66%, SMA50 149.8%, SMA200 211.61%). The stock’s 14-day RSI is 70.63 (overbought), while the ATR of 7.37 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.23% below its high and over 49248.27% above its low. Average 10-day trading volume of 1.92 million shares is significantly above the 3-month average of 372.98 thousand, indicating heightened recent market interest.

Regencell Bioscience Holdings Limited generated EPS of -$0.01 over the past year. Five-year average earnings growth is -33.47%.

Regencell Bioscience Holdings Limited has 494.49 million shares outstanding. The public float is 18.43 million shares, elevated short interest at 2.45% of float. This equals 2.26 million shares. The short ratio is 4.15 days. Institutional investors hold 3.64% of the float. Insiders own 96.16%. MILES AMY E holds 588.40 thousand shares, Ownby David has 229.57 thousand shares and BRANDOW PETER B has 212.72 thousand shares.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Regencell Bioscience Holdings Limited (NASDAQ:RGC) closed at $45.79 USD, gaining $4.37 (10.55%) from the previous close of $41.42. The stock is currently mid-range between its 52-week high and low $0.09 and $83.60. With a market capitalization of about $22.64 billion, Regencell Bioscience Holdings Limited is classified as a large-cap and shows higher-than-market volatility (beta ~2.02). Key stats such as the average daily volume over the past year has been around 376.35 thousand shares, trading with heavier-than-usual volume. Headquartered in Causeway Bay, None, Regencell Bioscience Holdings Limited operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Yat-Gai Au, the company employs approximately 12 people and listed since July 16, 2021. Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company.

Regencell Bioscience Holdings Limited trades at a P/E ratio of -6317.33, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4658.72 reflecting a rich premium to book value. The P/FCF stands at 0.0, also above market averages. Compared to sector medians, Regencell Bioscience Holdings Limited P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Regencell Bioscience Holdings Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.08%, with price expected at $49.03 by January 23, 2026, within a range of $43.21 to $54.91 3-Month Outlook: Projected fall of -83.21%, reaching $7.69 by April 09, 2026, with a range of $4.27 to $8.49. 1-Year Outlook: Projected loss of -41.19%, with price at $26.93 by December 31, 2026, within a range of $24.67 to $29.18.

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares are up 97.24% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Regencell Bioscience Holdings Limited trading at a premium to the broader market with a P/E of -6317.33. Our AI forecast model points to short-term strength (7.08% over two weeks), a medium-term fall (-83.21% over three months), and a longer-term loss (-41.19% over one year), with expected trading ranges indicating moderate volatility.